Cedars-Sinai scientists have developed an experimental drug that repairs DNA and serves as a prototype for a new class of ...
Experts released a new clinical guideline for effectively managing individuals diagnosed with hypertrophic cardiomyopathy (HCM). The guideline reiterates the importance of collaborative ...
TY1 enhances the action of TREX1, a gene that helps immune cells clear damaged DNA, helping to minimize scar tissue post heart attacks.
Updates to national guidelines for the management of hypertrophic cardiomyopathy (HCM) endorse cardiac myosin inhibitor use in certain cases, greenlight more intensive physical activity, and expand ...
Bristol Myers Squibb BMY suffered a setback in the late-stage ODYSSEY-HCM study evaluating cardiovascular drug Camzyos (mavacamten). The phase III study was evaluating Camzyos for the treatment of ...
Aficamten shows cardiac benefits over blood pressure drug metoprolol Analysts see potential for aficamten to replace beta-blocker drugs for treating HCM Cytokinetics plans to submit data to regulators ...
Novo Nordisk is adding on to its cardiovascular drug pipeline with the acquisition of Cardior Pharmaceuticals, a genetic medicines developer whose lead program is in mid-stage clinical testing in ...
Share on Pinterest Combining GLP-1 drugs like Ozempic with SGLT2 diabetes medications may help reduce the risk of heart attacks, stroke, and kidney disease, new research suggests. Alexandr Muşuc/Getty ...
CHARLESTOWN, Mass., July 08, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback